Extracorporeal shockwave therapy for Peyronie's disease: Who benefits?

Journal of Endourology

Volumn 20, Issue 2, 2006, Pages 135-138

  Taylor, Joby ^a   Forster, James A ^a   Browning, Anthony J ^a   Biyani, C Shekhar ^a  

^a PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CALCIFICATION; CLINICAL ARTICLE; CONFERENCE PAPER; DISEASE DURATION; DISEASE SEVERITY; EXTRACORPOREAL LITHOTRIPSY; HUMAN; MALE; OUTCOMES RESEARCH; PEYRONIE DISEASE; PILOT STUDY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEXUAL FUNCTION; TREATMENT OUTCOME;

ADULT; AGED; FOLLOW-UP STUDIES; HUMANS; LITHOTRIPSY; MALE; MIDDLE AGED; PATIENT SATISFACTION; PENILE INDURATION; TREATMENT OUTCOME;

EID: 33644833241     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2006.20.135     Document Type: Conference Paper

References (29)

1. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R. Helstrom W. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004;171:2350-2353.
2. Kadioglu A, Tefekli A, Erol B, Oktar T, Tune M, Tellaloglu S. A retrospective review of 307 men with Peyronie's disease. J Urol 2002;168:1075-1079.
3. Tornehl CK, Carson CC. Surgical alternatives for treating Peyronie's disease. BJU Int 2004;94:774-783.
4. Chahal R. Gogoi NK, Sundaram SK, Weston PMT. Corporal plication for penile curvature caused by Peyronie's disease: The patients' perspective. BJU Int 2001;87:352-356.
5. Incrocci L, Wijnmaalen A, Slob AK, Hop WCJ, Levendaq PC. Low dose radiotherapy in 179 patients with Peyronie's disease: Treatment outcome and current sexual functioning. Int J Radiat Oncol Biol Phys 2000;47:1353-1356.
6. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate in the treatment of Peyronie's disease: A prospective, placebo-controlled, randomised study. Eur Urol 2005;47:530-535.
7. Teloken C, Rhoden EL, Geazziotin TM, DA Ros CT, Sogiari PR, Souto CAV. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999;162:2003-2005.
8. Kadioglu A, Tefekli A, Koksal T, Usta M, Erol H. Treatment of Peyronie's disease with oral colchicine: Long-term results and predictive parameters of successful outcome. Int J Impot Res 2000;12:169-173.
9. Pryor JP, Farrell CF. Controlled clinical trial of vitamin E in Peyronie's disease. Prog Reprod Biol 1983;9:41-45.
10. Levine LA, Goldman KE, Greenfield JM. Experience with intralesional injection of verapamil for Peyronie's disease. J Urol 2002;168:621-625.
11. Brake M, Loertzer H, Horsch R, Keller H. Treatment of Peyronie's disease with local interferon-alpha 2b. BJU Int 2001;87:654-657.
12. Hamm R, McLarty E, Ashdown J, Natale S, Dickinson A. Peyronie's disease-The Plymouth experience of extracorporeal shockwave treatment. BJU Int 2001;87:849-852.
13. Lebret T, Loison G, Herve JM, et al. Extracorporeal shock wave therapy in the treatment of Peyronie's disease: Experience with a standard lithotripter (Siemens-Multiline). Urology 2002;59:657.
14. Hauck EW. Hauptmann A, Bschleipfer T, Schmelx HU, Altinkilic BM, Weidner W. Questionable efficacy of extracorporeal shock wave therapy for Peyronie's disease: Results of a prospective approach. J Urol 2004;171:296-299.
15. Manikandan R, Islam W, Srinivasan V, Evans CM. Evaluation of extracorporeal shock wave therapy in Peyronie's disease. Urology 2002;60:795-799.
16. Chilton CP, Castle WM, Westwood CA, Pryor JP. Factors associated in the aetiology of Peyronie's disease. Br J Urol 1982;54:748-750.
17. Carried MP, Serraino D, Palmiotto F, Nucci G, Sasso F. A case-control study on risk factors for Peyronie's disease. J Clin Epidemiol 1998;51:511-515.
18. Kehimi A. Classification of congenital and acquired penile deviation. Urol Int 1983;38:229-233.
19. Michel MS, Ptaschnyk T, Musial A, Braun P, Lenz ST, Alken P, Kohrmann KU. Objective and subjective changes in patients with Peyronie's disease after management with shockwave therapy. J Endourol 2003;17:41-44.
20. Hauck EW, Altinkilic BM, Ludwig M, Ludecke G, Schroeder-Printzen I, Arens C, Weidner W. Extracorporeal shock wave therapy in the treatment of Peyronie's disease: First results of a case controlled approach. Eur Urol 2000;38:663-670.
21. Levine LA, Latchamsetty KC. Treatment of erectile dysfunction in patienis with Peyronie's disease using sildenafil citrate. Int J Impot Res 2002;14:478-482.
22. Levine LA, Lenting EL. A surgical algorithm for the treatment of Peyronie's disease. J Urol 1997;158:2149-2152.
23. Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W. Extracorporeal shock wave therapy for Peyronie's disease: Exploratory meta-analysis of clinical trials. J Urol 2004;171:740-745.
24. Lebret T, Herve JM, Lugagne PM, Barre P, Orsini JL, Butreau M, Botto H. Extra-corporeal lithotripsy in the treatment of Peyronie's disease: Use of a standard lithotripter (Multiline Siemens) on 'young' (less than 6 months old) plaques. Prog Urol 2000;10:65-70.
25. Husain J, Lynn NNK, Jones DK, Collins GN, O'Reilly PH. Extracorporeal shock wave therapy in the management of Peyronie's disease: Initial experience. BJU Int 2000;86:466-468.
26. Ralph DJ. Minhas S. The management of Peyronie's disease. BJU Int 2004;93:208-215.
27. Haupt G, Chapvil M. The effect of shock waves on the healing of partial-thickness wounds in piglets. J Surg Res 199;49:45-48.
28. Cole AA, Cs-Szabo G, Levine L. Decreased collagenase in the tunica albuginea of older patients could contribute to the progression of Peyronie's plaque [abstract]. J Urol 2004;171(suppl 4):331.
29. Tefekli A, Kandirali E, Erol H, Alp T, Koksal T, Kadioglu A. Peyronie's disease in men under age 40: Characteristics and outcome. Int J Impot Res 2001;13:18-23.